B Cell Lymphoma
Conference Coverage
Targeted agents vs. chemoimmunotherapy as first-line treatment of CLL
SAN FRANCISCO – Experts debate the role of chemoimmunotherapy as first-line treatment of chronic lymphocytic leukemia.
Conference Coverage
Decoding biosimilar approvals
SAN FRANCISCO – Regulators must consider several factors when expanding the use of an approved biosimilar from one indication to another, based on...
Conference Coverage
German CLLM1 study: 4-year data raise concerns about lenalidomide maintenance
EDINBURGH – Four-year data from the CLLM1 study of lenalidomide maintenance after chemoimmunotherapy for CLL showed improved PFS and EFS versus...
Conference Coverage
ICLL-07 trial: MRD-driven strategy yields prolonged survival
EDINBURGH - In the phase 2 ICLL-07 trial, induction with obinutuzumab and ibrutinib followed by an MRD-driven treatment strategy for CLL yielded a...
Conference Coverage
GALACTIC CLL trial: Obinutuzumab consolidation helps eradicate MRD
EDINBURGH – Obinutuzumab consolidation after chemoimmunotherapy for B-CLL was highly effective for eradicating MRD within 6 months post...
From the Journals
ASCT may cure follicular lymphoma for some rituximab-naive patients
A retrospective cohort study suggests that ASCT, if performed promptly, can be curative in patients who have had an early failure of first-line...
From the Journals
CAR T-cell therapy found safe, effective for HIV-associated lymphoma
Two HIV-positive patients with chemotherapy-refractory, high-grade B-cell lymphoma achieved complete remission with anti-CD19 CAR T-cell therapy,...
From the Journals
Staging PET/CT better defines extent of mantle cell lymphoma
This type of imaging altered stage and management in nearly one-fifth of cases.
Feature
Could home care replace inpatient HSCT?
Researchers are conducting phase 2 trials comparing patients who receive all posttransplant care at home with patients treated in the hospital or...
From the Journals
Study confirms prognostic impact of MYC partner gene in DLBCL
The findings suggest that clinicians should adopt diagnostic strategies to identify this high-risk cohort of patients.
From the Journals
Rituximab, bendamustine look better than chemo alone in MCL
The research confirms the benefit of adding novel agents to chemotherapy regimens in older patients with mantle cell lymphoma.